February 5, 2025
San Diego-Based Biotech Startup Zafrens Secures Series A Additional funding to Advance Drug Discovery
San Diego, California, United States –
Zafrens, a pioneering platform that quickly isolates, cultures, images, and sequences millions of cells while linking molecular profiles to cell functions, has secured additional funding in its Series A round, bringing the total capital raised to USD 31 million. The extension, announced on February 4, 2025, saw participation from imec.xpand, along with existing investors Prime Movers Lab, Kofa Healthcare, and Global Brain Corporation. This new capital will allow Zafrens to scale its operations and forge new partnerships with pharmaceutical companies around the globe.
About Zafrens
founded in 2021 by Swamy Vijayan and Yi Zhang, Zafrens specializes in developing life sciences products that enable comprehensive characterization of diverse cell populations. The company’s platform integrates biology, chemistry, and engineering to generate deeper insights into drug interactions. The proprietary platform allows for full characterization of diverse cell populations, as well as directly correlating molecular profiles (DNA, RNA, protein) to cell phenotype and function.
Purpose of financing
The fresh capital will be utilized to expand Zafrens’ operational capacity and enhance its platform's capabilities. The company also plans to strengthen partnerships with pharmaceutical firms worldwide, advancing its mission to accelerate drug discovery across multiple therapeutic areas, including oncology, immunology, and neuroscience.
CEO’s Insights
Swamy Vijayan, CEO of Zafrens, emphasized:
"Our platform represents a fundamental shift in drug discovery. By simultaneously creating and testing a vast array of potential drugs, we provide researchers with unparalleled insights, accelerating the identification of promising treatments and benefiting patients faster."
Investor Perspective
Benoit Devogelaere, Partner at imec.xpand, stated:
"Zafrens exemplifies the breakthrough innovations we aim to support. Their platform, leveraging nanotechnology, has the potential to revolutionize the development of various modern medicines, including small molecules and advanced cell therapies."
Conclusion
By allowing researchers to test hundreds of thousands of potential drug candidates in a single experiment, Zafrens is transforming traditional drug discovery methods, significantly reducing the time and cost required to develop new treatments. With this funding, Zafrens is poised to scale its operations and further solidify its position in the biotech industry, driving innovation in drug discovery.
For more information, visit Zafrens on Linkedin.